Dosage of statin, cardiovascular comorbidities, and risk of atrial fibrillation: A nationwide population-based cohort study

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1131-1136

  Hung, Chen Ying ^a   Lin, Ching Heng ^a   Wang, Kuo Yang ^a,c   Huang, Jin Long ^a,b,c   Hsieh, Yu Cheng ^a,b   Loh, El Wui ^d   Lan, Tsuo Hung ^a   Chou, Pesus ^b   Ting, Chih Tai ^a,b   Wu, Tsu Juey ^a,b,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Atrial fibrillation; CHA2DS2VASc score; CHADS2 score; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATRIAL FIBRILLATION FREE SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR ACCIDENT; CHA2DS2VASC SCORE; CHADS2 SCORE; CHEMOPROPHYLAXIS; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

ATRIAL FIBRILLATION; CHA(2)DS(2)VASC SCORE; CHADS(2) SCORE; STATIN;

AGED; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; TAIWAN;

EID: 84885306020     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.11.087     Document Type: Article

References (34)

1. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229-34.
2. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009;54:2023-31.
3. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
4. Macfarlane PW, Murray H, Sattar N, et al. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace 2011;13:634-9.
5. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
6. Sandhu RK, Kurth T, Conen D, et al. Relation of renal function to risk for incident atrial fibrillation in women. Am J Cardiol 2012;109:538-42.
7. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14: 528-606.
8. CammAJ, Kirchhof P, Lip GY, et al.Guidelines for themanagement of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
9. Wang Z, Zhang Y,Gao M, et al. Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Pharmacotherapy 2011;31:1051-62.
10. Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2012;74:744-56.
11. Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008;51:828-35.
12. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92.
13. Tsan YT, Lee CH,Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012;30:623-30.
14. Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:236-42.
15. SLaC A. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.
16. Chiang CE,Wang TD, Li YH, et al. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc 2010;109:740-73.
17. Komatsu T, Tachibana H, Sato Y, et al. Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: comparison between atorvastatin and pravastatin. Int Heart J 2011;52:359-65.
18. Negi S, Shukrullah I, Veledar E, et al. Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol 2011;22:414-9.
19. Maggioni AP, Fabbri G, Lucci D, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009;30:2327-36.
20. Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J 2011;161:993-9.
21. Pellegrini CN, Vittinghoff E, Lin F, et al. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart 2009;95: 704-8.
22. Pena JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 2012;33:531-7.
23. Hung CY, Lin CH, Loh EW, et al. CHADS2 score, statin therapy, and risks of atrial fibrillation. Am J Med 2013 Feb;126(2):133-40.
24. Bang CN, Gislason GH, Greve AM et al. Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study. Eur J Prev Cardiol doi:10.1177/2047487312462804.
25. Koutbi L, Roy D, Talajic M, et al. Statins and atrial fibrillation in patients with left ventricular dysfunction: insights from the AF-CHF trial. Int J Cardiol 2013;165:575-7.
26. Liu T, Li L, Korantzopoulos P, et al. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008;126:160-70.
27. Bang CN, Greve AM, Abdulla J, et al. The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: A systematic review and meta-analysis. Int J Cardiol 2013;167:624-30.
28. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011;13: 308-28.
29. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001;47:403-11.
30. Maehama T, Okura H, Imai K, et al. Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation. Am J Cardiol 2010;106:535-8.
31. Crandall MA, Horne BD, Day JD, et al. Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently. Pacing Clin Electrophysiol 2009;32:648-52.
32. Ishii S, Karlamangla AS, Bote M, et al. Gender, obesity and repeated elevation of C-reactive protein: data from the CARDIA cohort. PLoS One 2012;7:e36062.
33. Amer MS, Elawam AE, Khater MS, et al. Association of high-sensitivity C-reactive protein with carotid artery intima-media thickness in hypertensive older adults. J Am Soc Hypertens 2011;5:395-400.
34. Wang TJ, Larson MG, Levy D, et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation 2002;106:1189-91.